KRYS Krystal Biotech Inc

Price (delayed)

$207.19

Market cap

$5.92B

P/E Ratio

104.64

Dividend/share

N/A

EPS

$1.98

Enterprise value

$5.57B

Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.

Highlights
The net income has soared by 142% YoY
The EPS has soared by 138% YoY
The company's quick ratio fell by 29% QoQ but it rose by 23% YoY

Key stats

What are the main financial stats of KRYS
Market
Shares outstanding
28.56M
Market cap
$5.92B
Enterprise value
$5.57B
Valuations
Price to earnings (P/E)
104.64
Price to book (P/B)
7.33
Price to sales (P/S)
61.1
EV/EBIT
94.14
EV/EBITDA
85.58
EV/Sales
58.01
Earnings
Revenue
$95.95M
EBIT
$59.13M
EBITDA
$65.04M
Free cash flow
$45.56M
Per share
EPS
$1.98
Free cash flow per share
$1.61
Book value per share
$28.25
Revenue per share
$3.39
TBVPS
$30.16
Balance sheet
Total assets
$853.3M
Total liabilities
$54.05M
Debt
$7.9M
Equity
$799.24M
Working capital
$554.66M
Liquidity
Debt to equity
0.01
Current ratio
12.66
Quick ratio
12.29
Net debt/EBITDA
-5.4
Margins
EBITDA margin
67.8%
Gross margin
94.3%
Net margin
59.6%
Operating margin
-70.4%
Efficiency
Return on assets
7.3%
Return on equity
7.7%
Return on invested capital
14.1%
Return on capital employed
7.3%
Return on sales
61.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KRYS stock price

How has the Krystal Biotech stock price performed over time
Intraday
0.16%
1 week
-0.65%
1 month
18.52%
1 year
72.21%
YTD
67.01%
QTD
12.82%

Financial performance

How have Krystal Biotech's revenue and profit performed over time
Revenue
$95.95M
Gross profit
$90.44M
Operating income
-$67.59M
Net income
$57.16M
Gross margin
94.3%
Net margin
59.6%
The net margin has soared by 176% from the previous quarter
The net income has soared by 142% YoY
The gross profit has soared by 90% QoQ
The revenue has surged by 89% since the previous quarter

Growth

What is Krystal Biotech's growth rate over time

Valuation

What is Krystal Biotech stock price valuation
P/E
104.64
P/B
7.33
P/S
61.1
EV/EBIT
94.14
EV/EBITDA
85.58
EV/Sales
58.01
The EPS has soared by 138% YoY
KRYS's P/B is 98% above its 5-year quarterly average of 3.7 and 49% above its last 4 quarters average of 4.9
Krystal Biotech's equity has surged by 63% YoY and by 2.6% QoQ
The revenue has surged by 89% since the previous quarter

Efficiency

How efficient is Krystal Biotech business performance
The ROS has soared by 143% from the previous quarter
Krystal Biotech's return on invested capital has surged by 138% YoY
Krystal Biotech's ROA has soared by 131% YoY
The ROE has soared by 130% YoY

Dividends

What is KRYS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRYS.

Financial health

How did Krystal Biotech financials performed over time
The company's total assets has surged by 60% YoY and by 4.3% QoQ
The total liabilities has grown by 36% from the previous quarter and by 28% YoY
The debt is 99% less than the equity
Krystal Biotech's equity has surged by 63% YoY and by 2.6% QoQ
The debt to equity has plunged by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.